- Coordinator
- Universita Degli Studi Di Roma Tor Vergata, Italy
- Runs
- 1 March 2027 to 28 February 2031
- Status
- Running
- EU funding
- €1.6m
- Total cost
- —
- Partners
- 14 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101343634
What the project is doing
In the project's own words, from its summary on CORDIS.
ARMOR addresses a major challenge in modern medicine: chronic biofilm-associated infections, which are highly resistant to antibiotics and closely linked to antimicrobial resistance. The project will develop a new generation of safe, biomimetic nanovesicles inspired by bacterial outer membrane vesicles that can penetrate biofilms and deliver therapeutics directly to the infection site. By combining detoxified bacterial membrane components with synthetic lipids and responsive materials, ARMOR aims to create programmable vesicles that release their cargo only under biofilm-specific conditions such as acidic pH or bacterial enzymes.
The platform will integrate multiple antimicrobial strategies, including antibiotics, antimicrobial peptides, enzymes, and light- and ultrasound-activated agents, to achieve targeted and synergistic biofilm eradication. A distinctive feature of ARMOR is its closed design-build-test-learn framework, in which artificial intelligence, advanced imaging, and quantitative in vitro and in vivo data are combined to iteratively optimise vesicle design, delivery, efficacy, and safety.
The project brings together an international, interdisciplinary, and intersectoral consortium spanning academia and industry across Europe and beyond. Through structured staff secondments, shared training, and joint research activities, ARMOR will promote deep transfer of knowledge and build durable collaboration networks. ARMOR is expected to deliver validated preclinical lead formulations, AI-enabled optimisation workflows, and scalable approaches for vesicle production, stabilisation, and quality control.
In the longer term, the project will strengthen Europe’s capacity to develop precision anti-infective therapies, reduce reliance on conventional antibiotics, and improve the management of chronic biofilm infections and antimicrobial resistance.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Coordinator |
| Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet) | Buenos Aires | AR | Associatedpartner |
| Fundacao Para O Desenvolvimento Da Unesp - Fundunesp | Sao Paulo | Brazil | Associatedpartner |
| Nexus Biosolutions SA | Plan Les Ouates | Switzerland | Participant |
| Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Erlangen | Germany | Participant |
| Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic Biomagune | San Sebastian | Spain | Participant |
| GlobeVAC Oy | Espoo | Finland | Participant |
| Helsingin Yliopisto | Helsinki | Finland | Participant |
| Maibe SRL | Roma | Italy | Participant |
| Universita Degli Studi Di Catania | Catania | Italy | Participant |
| Lebanese American University | Beirut | LB | Associatedpartner |
| Universite Cheikh Anta Diop De Dakar | Dakar Fann | SN | Associatedpartner |
| Chulalongkorn University | Bangkok | TH | Associatedpartner |
| Acibadem Mehmet Ali Aydinlar University | Istanbul | Türkiye | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS